A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

NCT03268083 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Enterovirus Infections

Interventions

BIOLOGICAL: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
BIOLOGICAL: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
BIOLOGICAL: EV71 vaccine ([1 μg total protein ] per dose)

Sponsor

Enimmune Corporation